Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program
- PMID: 21399484
- PMCID: PMC3288449
- DOI: 10.1097/WAD.0b013e318212c0df
Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program
Abstract
Background: Primary care providers routinely evaluate older adults and are thus in a position to first detect symptoms and signs of Alzheimer disease. In urban areas, diagnostic or management difficulties may be referred to specialists; however, in rural areas, specialists may not be available. The Clinician Partners Program (CPP) was initiated to enhance rural health providers' ability in the diagnosis of dementia and care, and to increase research recruitment into dementia research studies of participants from rural communities.
Methods: The CPP is a 3-day "miniresidency" of didactic, observational, and skill-based teaching techniques. Participants completed pretests and posttests evaluating dementia knowledge, confidence in providing care, and practice behaviors.
Results: Between 2000 and 2009, 146 health care professionals with a mean age of 45.7±10.8 years attended the CPP; 79.2% were white, 58.2% were women, and 58% of participants had been in practice for more than 10 years. Posttests showed an improvement in knowledge and confidence for diagnosis and treatment and increased the use of dementia screening tools. Rural research participation in an urban Alzheimer Disease Research Center increased 52% over the pre-CPP period.
Conclusions: The following primary goals were accomplished: increased knowledge and confidence, changed practice habits, and enhanced research recruitment. Educational programs such as the CPP may be beneficial for increasing access to accurate diagnoses and appropriate treatment for Alzheimer disease while also enhancing research participation.
(C) 2012 Lippincott Williams & Wilkins, Inc.
Figures
References
-
- Alzheimer Association. [Accessed April 13, 2010.];2010 http://www.alz.org/alzheimers_disease_facts_figures.asp.
-
- Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimer Dement. 2010;6:98–103. - PubMed
-
- Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psych. 2006;21:17–28. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
